盛新鋰能(002240.SZ):目前公司已建成鋰鹽產能7萬噸
格隆匯5月15日丨有投資者在投資者互動平台向盛新鋰能(002240.SZ)提問,“sabi star鋰礦試產後,預計爬坡多久可全產?另外全產後公司的鋰精礦自給率可達到多少百分比呢?”
盛新鋰能回覆稱,公司將充分發揮在礦山開發運營方面的優勢,做好各項工作,盡最快速度推動薩比星礦山達產。目前公司已建成鋰鹽產能7萬噸;鋰資源方面,公司控股的奧伊諾礦業已建成鋰精礦生產規模約為7.5萬噸/年(摺合碳酸鋰約1萬噸);公司控股的津巴布韋薩比星礦山已建成鋰精礦生產規模約為20萬噸/年。未來公司將持續加強對境內外鋰礦資源的關注,不斷提升鋰礦石原料的自給率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.